Cost analysis of inappropriate treatments for suspected dermatomycoses

Emanuela Fiammenghi, Angela Patalano, Viviana Lo Conte, Gabriella Calabrò



Superficial mycoses are estimated to affect more than 20-25% of the world’s population with a consistent increase over the years. Most patients referred to our clinic for suspected dermatomycoses have already been treated with pharmacotherapy, without a previous mycological examination and many show changes in the clinical manifestations. Indeed, some medications, such as steroids, antiviral, antibiotics and antihistamines are not able to erase a fungal infection, but also they can cause atypical clinical manifestations. The consequences of inappropriate treatment include delayed diagnosis, prolonged healing time, and additional costs. The aims of this study were (1) to evaluate the incidence of increased costs attributable to inappropriate therapy sustained by the National Health Service and patients and (2) to highlight the importance of mycological evaluation before starting treatment, in order to improve diagnostic accuracy. An observational retrospective and prospective study was performed from September 2013 to February 2014, in 765 patients referred to our center (University Hospital “ Federico II”) in Naples, Italy, for suspected mycological infection. The following treatments (alone or in combination) were defined as inappropriate: (1) cortisone in a patient with at least one positive site; (2) antifungals in (a) patients with all negative sites or (b) ineffective antifungal treatment (in terms of drug chosen, dose or duration) in those with all positive sites; or (3) antibiotics; (4) antivirals or (5) antihistamines, in patients with ≥ 1 positive site. Five hundred and fifty patients were using medications before the assessment visit. The total amount of avoidable costs related to inappropriate previous treatments was € 121,417, representing 74% of the total treatment costs. 253/550 patients received drugs also after the visit. For these patients, the cost of treatment prescribed after mycological testing was € 42,952, with a decrease with respect to the total consumption of drugs at the time of access to the Mycology Laboratory of € 34,781. Thus, our cost analysis shows that it is important to obtain a reduction of costs for pathologies that need to be confirmed by examinations before starting treatment.


Cost-analysis; Inappropriate treatments; Dermatomycoses; Mycological examination

Full Text:



  • Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008; 51 Suppl 4: 2-15;
  • Feuilhade de Chauvin M. New diagnostic techniques. J Eur Acad Dermatol Venereol 2005; 19 Suppl 1: 20-4;
  • SIDeMaST. Micosi superficiali: linee guida e raccomandazioni SIDeMaST 2014. Available at (last accessed April 2015)
  • Janković A, Binić I, Gligorijević J, et al. Mimicking each other: psoriasis with tinea incognito. Dermatologica Sinica 2011; 29: 149;
  • Romano C, Maritati E, Gianni C. Tinea incognito in Italy: a 15-year survey. Mycoses 2006; 49: 383-7;
  • Atzori L, Pau M, Aste N, et al. Dermatophyte infections mimicking other skin diseases: a 154-person case survey of tinea atypica in the district of Cagliari (Italy). Int J Dermatol 2012; 51: 410-5;
  • Finlay AY, Long CC. The finger-tip unit-a new practical measure. Clin Exp Dermatol 1991; 16: 444-7;
  • 2014: Handbook Pharmaceutical/Database Federfarma
  • Accordo collettivo nazionale per la disciplina dei rapporti con i medici di medicina generale ai sensi dell’art. 8 DL 512 e successive modificazioni ed integrazioni, anno 2010
  • Regione Campania. Bollettino ufficiale della regione Campania. Available at (last accessed April 2015)
  • iDoctors. Prestazioni e prezzi medi nelle regioni indicate. Available at (last accessed April 2015)
  • Regione Campania. Bollettino ufficiale della regione Campania. Decreto n. 61 del 26.09.2011. Available at (last accessed April 2015)
  • Lu YC, Ross-Degnan D, Soumerai SB, et al. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007. BMC Health Serv Res 2008; 8: 75;
  • Galván Banqueri M, Alfaro Lara ER, Rincón Gómez M, et al. Factors related with the appropriateness of pharmacological treatment in polypathological patients. Farm Hosp 2014; 38: 405-10
  • Tan Y, Lin L, Feng P, et al. Dermatophytosis caused by Trichophyton rubrum mimicking syphilid: a case report and review of literature. Mycoses 2014; 57: 312-5;
  • Ruiz Rivero J, Mendoza Cembranos MD, Ciudad Blanco MC. Ti-a incógnita: serie de casos y revisión bibliográfica. Piel 2014; 29: 624
  • Sun PL, Ho HT, Concentric rings: an unusual presentation of tinea corporis caused by Microsporum gypseum. Mycoses 2006; 49: 150-1;
  • Urbina F, Sudy E, Barrios M. Ti-a incógnita. Piel 2002; 17: 12;
  • Zisova LG, Dobrev HP, Tchernev G, et al. Tinea atypica: report of nine cases. Wien Med Wochenschr 2013; 163: 549-55;
  • Pérez Fuentes MF, Castillo Castillo R, Rodríguez Toquero J, et al. Adecuación del tratamiento farmacológico en población anciana polimedicada. Medicina de Familia 2002; 1: 23-8
  • Shorr AF, MIcek ST, Kollef MH. Inappropriate therapy for methicillin-resistant Stalhylococcus aureus: resource utilization and cost implications. Crit Care Med 2008; 36: 2335-40;
  • van Walraven C, Naylor CD. Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits. JAMA 1998; 280: 550-8;
  • Arnold HM, Micek ST, Shorr AF, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010; 30: 361-8;
  • Ojeniran M, Shouval R, Miskin IN, et al. Costs of appropriate and inappropriate use of antibiotics in the emergency department. Isr Med Assoc J 2010; 12: 742-6


  • There are currently no refbacks.

© SEEd srl